A study to assess the safety and efficacy of chemotherapy and surgery in treatment of cervical cancer

Not Applicable

Completed

• Conditions: Feasibility of NACT in localized advanced cervical cancer patients; Cancer

• Registration Number: ISRCTN24104022
• Lead Sponsor: nion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Brief Summary

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35996118/ (added 23/08/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-05-01
• Study Start: 2022-07-13
• Last Update Posted: 5 September 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 414

Inclusion Criteria

1. Primary malignant tumor of cervix confirmed by cervical biopsy
2. No other malignant tumors

Exclusion Criteria

1. Cervical metastatic malignant tumor
2. Complicated with other malignant tumors
3. Patients undergoing surgery or pathological examination in other hospitals

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
5-year overall survival defined as the time from completion of operation to death or to the date of last contact.

Secondary Outcome Measures

Name	Time	Method
<br> 1. 5-year progression-free survival defined as the time from completion of operation to the first appearance of progressive disease or to the date of last contact<br> 2. Cumulative postoperative radiation rate: use of radiation and the interval between surgery and radiation (adjuvant therapy or therapy after recurrence) were used to estimate the cumulative radiation during the follow-up<br>